MXPA02012308A - Nuevo interferon para el tratamiento de esclerosis multiple. - Google Patents
Nuevo interferon para el tratamiento de esclerosis multiple.Info
- Publication number
- MXPA02012308A MXPA02012308A MXPA02012308A MXPA02012308A MXPA02012308A MX PA02012308 A MXPA02012308 A MX PA02012308A MX PA02012308 A MXPA02012308 A MX PA02012308A MX PA02012308 A MXPA02012308 A MX PA02012308A MX PA02012308 A MXPA02012308 A MX PA02012308A
- Authority
- MX
- Mexico
- Prior art keywords
- multiple sclerosis
- treatment
- bgr
- biologically
- novel interferon
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 2
- 102000014150 Interferons Human genes 0.000 title 1
- 108010050904 Interferons Proteins 0.000 title 1
- 229940079322 interferon Drugs 0.000 title 1
- 229920001184 polypeptide Chemical group 0.000 abstract 2
- 108090000765 processed proteins & peptides Chemical group 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 102000004889 Interleukin-6 Human genes 0.000 abstract 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Esta invencion se refiere a nuevos acidos nucleicos y secuencias de polipeptidos, que codifican para un interferon-(-2 ("FN-(2"). Una composicion farmaceutica, que comprende un excipiente farmaceuticamente aceptable de una cantidad terapeuticamente efectiva de un polipeptido de IFN-(2 humano, fragmento biologicamente activo del mismo, o un derivado biologicamente activo del mismo, es util en el tratamiento de la esclerosis multiple en humanos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21204600P | 2000-06-16 | 2000-06-16 | |
| US09/881,050 US20020025304A1 (en) | 2000-06-16 | 2001-06-15 | Novel interferon for the treatment of multiple sclerosis |
| PCT/US2001/041022 WO2001095929A2 (en) | 2000-06-16 | 2001-06-18 | Interferon for treatment of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02012308A true MXPA02012308A (es) | 2003-04-25 |
Family
ID=26906704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02012308A MXPA02012308A (es) | 2000-06-16 | 2001-06-18 | Nuevo interferon para el tratamiento de esclerosis multiple. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20020025304A1 (es) |
| EP (1) | EP1289541A2 (es) |
| JP (1) | JP2004505021A (es) |
| KR (1) | KR20030009529A (es) |
| CN (1) | CN1436086A (es) |
| AU (1) | AU2001267099A1 (es) |
| BG (1) | BG107370A (es) |
| BR (1) | BR0111852A (es) |
| CA (1) | CA2413077A1 (es) |
| CZ (1) | CZ20024094A3 (es) |
| EE (1) | EE200200693A (es) |
| HU (1) | HUP0300787A2 (es) |
| IL (1) | IL152996A0 (es) |
| LT (1) | LT2002123A (es) |
| MX (1) | MXPA02012308A (es) |
| NO (1) | NO20025964L (es) |
| NZ (1) | NZ522849A (es) |
| PL (1) | PL359562A1 (es) |
| RU (1) | RU2003100517A (es) |
| SI (1) | SI21080A (es) |
| SK (1) | SK17612002A3 (es) |
| WO (1) | WO2001095929A2 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ540043A (en) * | 2002-11-18 | 2007-11-30 | Maxygen Inc | Isolated or recombinant Interferon-alpha polypeptides and conjugates |
| US7314613B2 (en) * | 2002-11-18 | 2008-01-01 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
| EP1712992A1 (en) * | 2005-04-11 | 2006-10-18 | Sony Ericsson Mobile Communications AB | Updating of data instructions |
| WO2011103164A1 (en) * | 2010-02-18 | 2011-08-25 | Centocor Ortho Biotech Inc. | Monkey homolog of human interferon omega |
| DK3411398T3 (da) | 2016-02-05 | 2024-06-24 | Orionis Biosciences BV | Målrettede terapeutiske midler og anvendelse heraf |
| US11384154B2 (en) | 2017-02-06 | 2022-07-12 | Orionis Biosciences BV | Targeted chimeric proteins and uses thereof |
| JP7586579B2 (ja) | 2017-02-06 | 2024-11-19 | オリオンズ バイオサイエンス インコーポレイテッド | 標的化改変型インターフェロン及びその使用 |
| US20200354424A1 (en) | 2018-01-26 | 2020-11-12 | Orionis Biosciences, Inc. | Xcr1 binding agents and uses thereof |
| WO2024192373A1 (en) * | 2023-03-16 | 2024-09-19 | A-Alpha Bio | Interferon alpha-2 variants |
| US12281147B2 (en) | 2023-08-14 | 2025-04-22 | A-Alpha Bio, Inc. | Interleukin 21 variants |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6372206B1 (en) * | 1989-03-02 | 2002-04-16 | University Of Florida | Orally-administered interferon-TAU compositions and methods |
| EP0758902A1 (en) * | 1994-05-10 | 1997-02-26 | Immulogic Pharmaceutical Corporation | Compositions and treatment for multiple sclerosis |
| IL136326A0 (en) * | 1997-12-08 | 2001-05-20 | Genentech Inc | Human interferon-epsilon: a type i interferon |
| EA200001252A1 (ru) * | 1998-05-29 | 2001-06-25 | Байоджен, Инк. | КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА-β-1A(IFN-β-1A) ЧЕЛОВЕКА |
| IL142061A0 (en) * | 1998-09-18 | 2002-03-10 | Zymogenetics Inc | Interferon-epsilon |
| US20030175897A1 (en) * | 2000-04-14 | 2003-09-18 | Thayer Edward C. | Human interferon, Zinf2 |
-
2001
- 2001-06-15 US US09/881,050 patent/US20020025304A1/en not_active Abandoned
- 2001-06-18 IL IL15299601A patent/IL152996A0/xx unknown
- 2001-06-18 CZ CZ20024094A patent/CZ20024094A3/cs unknown
- 2001-06-18 HU HU0300787A patent/HUP0300787A2/hu unknown
- 2001-06-18 EE EEP200200693A patent/EE200200693A/xx unknown
- 2001-06-18 SI SI200120032A patent/SI21080A/sl not_active IP Right Cessation
- 2001-06-18 EP EP01944716A patent/EP1289541A2/en not_active Withdrawn
- 2001-06-18 SK SK1761-2002A patent/SK17612002A3/sk unknown
- 2001-06-18 AU AU2001267099A patent/AU2001267099A1/en not_active Abandoned
- 2001-06-18 CN CN01811184A patent/CN1436086A/zh active Pending
- 2001-06-18 PL PL01359562A patent/PL359562A1/xx not_active Application Discontinuation
- 2001-06-18 WO PCT/US2001/041022 patent/WO2001095929A2/en not_active Application Discontinuation
- 2001-06-18 BR BR0111852-8A patent/BR0111852A/pt not_active Application Discontinuation
- 2001-06-18 NZ NZ522849A patent/NZ522849A/en unknown
- 2001-06-18 MX MXPA02012308A patent/MXPA02012308A/es unknown
- 2001-06-18 CA CA002413077A patent/CA2413077A1/en not_active Abandoned
- 2001-06-18 RU RU2003100517/15A patent/RU2003100517A/ru not_active Application Discontinuation
- 2001-06-18 JP JP2002510107A patent/JP2004505021A/ja active Pending
- 2001-06-18 KR KR1020027017090A patent/KR20030009529A/ko not_active Withdrawn
-
2002
- 2002-12-02 LT LT2002123A patent/LT2002123A/xx unknown
- 2002-12-11 BG BG107370A patent/BG107370A/xx unknown
- 2002-12-12 NO NO20025964A patent/NO20025964L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001267099A1 (en) | 2001-12-24 |
| WO2001095929A2 (en) | 2001-12-20 |
| PL359562A1 (en) | 2004-08-23 |
| NO20025964L (no) | 2003-02-14 |
| KR20030009529A (ko) | 2003-01-29 |
| LT2002123A (en) | 2003-06-25 |
| CN1436086A (zh) | 2003-08-13 |
| WO2001095929A3 (en) | 2002-10-10 |
| SI21080A (sl) | 2003-06-30 |
| EE200200693A (et) | 2004-06-15 |
| JP2004505021A (ja) | 2004-02-19 |
| EP1289541A2 (en) | 2003-03-12 |
| IL152996A0 (en) | 2003-06-24 |
| BR0111852A (pt) | 2003-05-20 |
| BG107370A (en) | 2003-11-28 |
| NZ522849A (en) | 2004-05-28 |
| RU2003100517A (ru) | 2004-06-27 |
| HUP0300787A2 (hu) | 2003-07-28 |
| US20020025304A1 (en) | 2002-02-28 |
| SK17612002A3 (sk) | 2003-08-05 |
| NO20025964D0 (no) | 2002-12-12 |
| CZ20024094A3 (cs) | 2003-05-14 |
| CA2413077A1 (en) | 2001-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ271756A (en) | Human macrophage inflammatory proteins and coding sequences, their production and use | |
| CA2184908A1 (en) | Human osteoclast-derived cathepsin | |
| MX9703643A (es) | Metodos para tratamiento de esclerosis multiple usando analogos de peptidos de proteina basica de mielina humana. | |
| EP1197220A3 (en) | Therapeutic methods and compositions based on delta proteins and nucleic acids | |
| EP1918300A3 (en) | Peptide-based immunization therapy for treatment of atherosclerosis | |
| EP1033998A4 (en) | METHOD FOR SUPPRESSING BETA AMYLOID-RELATED CHANGES IN ALZHEIMER | |
| AU6020099A (en) | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein | |
| IL134345A0 (en) | Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon | |
| MY118526A (en) | Method for improving the pharmacokinetics of tipranavir | |
| MXPA02012308A (es) | Nuevo interferon para el tratamiento de esclerosis multiple. | |
| DK1259536T3 (da) | Fremgangsmåder til peptidfremstilling | |
| DE69736276D1 (de) | Menschliche dnase resistent gegen actininhibitoren | |
| UA83989C2 (ru) | Выделенный пептид, который стимулирует противоопухолевый иммунный ответ, фармацевтическая композиция на его основе и ее применение | |
| DK0938329T3 (da) | Immunogen TLP sammensætning | |
| BG101846A (en) | HUMAN DNase I VARIANTS | |
| PL375354A1 (en) | Use of treosulfan and derivatives thereof for treating multiple sclerosis | |
| CA2242562A1 (en) | Human dnase resistant to actin inhibition | |
| WO2001045729A8 (fr) | Nouveau polypeptide, phosphoproteine ribosomale humaine 16, et polynucleotide codant pour ce polypeptide | |
| WO2001075016A3 (fr) | Nouveau polypeptide, tyrosinase humaine 16, et polynucleotide codant pour ce polypeptide | |
| WO2001075057A3 (fr) | Nouveau polypeptide, proteine ribosomale s4 humaine 12, et polynucleotide codant pour ce polypeptide | |
| WO2001075022A3 (fr) | Nouveau polypeptide, eucaryon acetyl transferase humaine 12, et polynucleotide codant pour ce polypeptide | |
| WO2001075026A3 (fr) | Nouveau polypeptide, eucaryote acetyl transferase humaine 10, et polynucleotide codant pour ce polypeptide | |
| WO2001075012A3 (fr) | Nouveau polypeptide, peptide signal humain 10 d'une proteine precurseur de la lipoproteine, et polynucleotide codant pour ce polypeptide | |
| WO2001081535A3 (fr) | Nouveau polypeptide, proteine pax humaine 9.9, et polynucleotide codant pour ce polypeptide | |
| WO2001075046A3 (fr) | Nouveau polypeptide, gene humain de regulation 17 du cycle mitotique, et polynucleotide codant pour ce polypeptide |